Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CALT vs. ACLX, ADMA, RARE, APLS, BHVN, IMVT, RNA, SRRK, OGN, and PTCTShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Arcellx (ACLX), ADMA Biologics (ADMA), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Biohaven (BHVN), Immunovant (IMVT), Avidity Biosciences (RNA), Scholar Rock (SRRK), Organon & Co. (OGN), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. Arcellx ADMA Biologics Ultragenyx Pharmaceutical Apellis Pharmaceuticals Biohaven Immunovant Avidity Biosciences Scholar Rock Organon & Co. PTC Therapeutics Arcellx (NASDAQ:ACLX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking. Is ACLX or CALT more profitable? Arcellx has a net margin of -25.94% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Arcellx's return on equity of -8.28% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Arcellx-25.94% -8.28% -5.21% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Does the MarketBeat Community favor ACLX or CALT? Arcellx received 41 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 82.93% of users gave Arcellx an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformArcellxOutperform Votes6882.93% Underperform Votes1417.07%Calliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Does the media refer more to ACLX or CALT? In the previous week, Arcellx had 10 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 10 mentions for Arcellx and 0 mentions for Calliditas Therapeutics AB (publ). Arcellx's average media sentiment score of 0.78 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Arcellx is being referred to more favorably in the media. Company Overall Sentiment Arcellx Positive Calliditas Therapeutics AB (publ) Neutral Do analysts rate ACLX or CALT? Arcellx presently has a consensus target price of $105.93, indicating a potential upside of 29.14%. Calliditas Therapeutics AB (publ) has a consensus target price of $39.25, indicating a potential downside of 1.88%. Given Arcellx's stronger consensus rating and higher possible upside, equities analysts plainly believe Arcellx is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher earnings & valuation, ACLX or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcellx$155.82M28.47-$70.69M-$0.71-115.53Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Which has more risk & volatility, ACLX or CALT? Arcellx has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Do insiders & institutionals have more ownership in ACLX or CALT? 96.0% of Arcellx shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 6.2% of Arcellx shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryArcellx beats Calliditas Therapeutics AB (publ) on 15 of the 19 factors compared between the two stocks. Ad DTIWill the Nasdaq 100 crash?In a world where some top money managers say you should “diversify” with a basket of stocks to help lower risk in your portfolio… And others say you should focus on only one ticker at a time because you can’t really keep detailed tabs on 10, 20 or more stocks at once… My #1 strategy to play the Nasdaq bull run has shown the power to provide the best of BOTH worlds at the same time. Because it harnesses ONE ticker that bottles up all the firepower of Apple, Nvidia, Tesla and more into one place… While I cannot promise future returns or against losses… This strategy targets major payouts OVERNIGHT!Click here to get the details. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-21.6210.71135.1917.53Price / Sales0.74287.971,224.59140.21Price / CashN/A56.6540.6537.95Price / Book37.745.394.884.92Net Income-$43.96M$152.04M$118.97M$225.78M7 Day PerformanceN/A-4.32%15.53%-1.58%1 Month PerformanceN/A2.80%15.54%6.67%1 Year Performance77.70%17.30%34.63%22.48% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180ACLXArcellx3.0444 of 5 stars$85.05+1.5%$105.93+24.5%+60.5%$4.60B$155.82M-118.03130ADMAADMA Biologics3.8605 of 5 stars$19.13+2.9%$21.25+11.1%+343.6%$4.52B$382.81M68.32530Short Interest ↓RAREUltragenyx Pharmaceutical4.5695 of 5 stars$46.29+1.1%$87.46+88.9%-2.2%$4.27B$434.25M-7.081,276APLSApellis Pharmaceuticals4.721 of 5 stars$33.34+0.5%$49.94+49.8%-34.5%$4.15B$396.59M-16.35702Analyst DowngradeShort Interest ↓Positive NewsBHVNBiohaven3.8327 of 5 stars$40.23+4.6%$63.00+56.6%+0.3%$4.07B$462.51M-4.11239Analyst ForecastIMVTImmunovant1.4499 of 5 stars$27.63+5.1%$47.89+73.3%-34.7%$4.06BN/A-11.84120RNAAvidity Biosciences2.5121 of 5 stars$33.85+4.2%$63.60+87.9%+278.5%$4.04B$10.12M-11.28190Gap DownSRRKScholar Rock3.9591 of 5 stars$43.13+2.7%$40.43-6.3%+130.0%$4.04B$33.19M-18.35140Positive NewsOGNOrganon & Co.4.851 of 5 stars$14.71-3.9%$21.33+45.0%+12.9%$3.79B$6.26B2.9110,000PTCTPTC Therapeutics3.9956 of 5 stars$47.80+3.1%$54.08+13.1%+65.6%$3.69B$937.82M-7.811,410Positive News Related Companies and Tools Related Companies Arcellx Alternatives ADMA Biologics Alternatives Ultragenyx Pharmaceutical Alternatives Apellis Pharmaceuticals Alternatives Biohaven Alternatives Immunovant Alternatives Avidity Biosciences Alternatives Scholar Rock Alternatives Organon & Co. Alternatives PTC Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CALT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
